The United States’ (US) Food and Drug Administration (FDA) 501(k) clearance of cerebrospinal fluid (CSF) biomarkers of amyloid (A) and tau (T) [1], the hallmark pathologies of AD, brought that goal within reach, but still within the remit of specialist care. This evidence concerns the gene MAPT and Alzheimer disease.